Close Menu

Colorectal Cancer

News and reporting on colorectal cancer.

Germany's Epigenomics and life science outsourcing firm NextPharma have signed a global manufacturing contract covering Epi proColon, Epigenomics' nucleic acid amplification-based colorectal cancer screening test.

NextPharma will manufacture Epigenomics' Epi proColon test kit in Europe and other markets.

Keeping an eye on growing its global presence and test menu, Genomic Health does not plan to significantly grow its profits in future years, but will instead reinvest that money into research and development efforts.

The Sydney, Australia-based firm obtained worldwide, exclusive rights to Garvan's cancer-associated methylation DNA biomarkers for the diagnosis and/or treatment of colorectal cancer.

The merger will give Biosystems International access to MicroBioChips' nanoarray technology and its sales and marketing resources, which are expected to help the company establish new relationships with university-based proteomics laboratories and pharma and biotech firms.

Recently, Mao Mao, a research fellow at Pfizer Oncology Research who is working on several different cancer sequencing projects, spoke to In Sequence about the company's use of sequencing in drug development and the hurdles that still remain in implementing the technology in pharmaceutical research.

GeneNews recently presented a study that found ColonSentry "was able to detect right-sided CRC lesions across all stages with a sensitivity that is at least equal to the detection observed for left-sided lesions."

Enzo has been awarded a license to provide clinical diagnostic services in Pennsylvania, which could help the eventual uptake of ColonSentry, a PCR-based colon cancer risk-stratification test manufactured by Canadian firm GeneNews and for which Enzo has exclusive distribution rights in New York and New Jersey.

Petricoin said the database could help physicians make better treatment decisions, aid pharmaceutical firms' drug-development efforts, and uncover new indications for existing therapies.

While Genomic Health projects "more modest" growth for its legacy node-negative breast cancer business over the next year, newer markets in which the company is still working to secure reimbursement still represent a significant opportunity for expansion in the years ahead.

Pages

A new study finds that three dimensional facial scans may be able to aid in diagnosing rare genetic diseases.

The Lancet and the New England Journal of Medicine have retracted two COVID-19 papers due to concerns about the data used in their analyses.

Lawmakers plan to introduce a bill that aims to prevent the theft of US-funded research, according to the Wall Street Journal.

In Science this week: analysis of ancient Caribbean islanders' genomes suggests at least three waves of migration into the region,  DNA barcoding of microbial spores, and more.